These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38306539)

  • 21. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group.
    Christou NV; Turgeon P; Wassef R; Rotstein O; Bohnen J; Potvin M
    Arch Surg; 1996 Nov; 131(11):1193-201. PubMed ID: 8911260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials.
    Lin MH; Shen YC; Cheng HY; Teng CK; Chen WC; Lin YC; Hung CC
    J Glob Antimicrob Resist; 2023 Sep; 34():46-58. PubMed ID: 37328062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
    Kohno S; Bando H; Yoneyama F; Kikukawa H; Kawahara K; Shirakawa M; Aoyama N; Brown M; Paschke A; Takase A
    J Infect Chemother; 2021 Feb; 27(2):262-270. PubMed ID: 33191112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eravacycline for the treatment of patients with bacterial infections.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Apr; 54(4):245-254. PubMed ID: 29869646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).
    Cantón R; Loza E; Aznar J; Castillo FJ; Cercenado E; Fraile-Ribot PA; González-Romo F; López-Hontangas JL; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
    Rev Esp Quimioter; 2019 Apr; 32(2):145-155. PubMed ID: 30761824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EUropean prospective cohort study on
    Gutiérrez-Gutiérrez B; Sojo-Dorado J; Bravo-Ferrer J; Cuperus N; de Kraker M; Kostyanev T; Raka L; Daikos G; Feifel J; Folgori L; Pascual A; Goossens H; O'Brien S; Bonten MJ; Rodríguez-Baño J;
    BMJ Open; 2017 Apr; 7(4):e015365. PubMed ID: 28373258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carbapenem susceptibilities of Gram-negative pathogens in intra-abdominal and urinary tract infections: updated report of SMART 2015 in China.
    Zhang H; Kong H; Yu Y; Wu A; Duan Q; Jiang X; Zhang S; Sun Z; Ni Y; Wang W; Wang Y; Liao K; Li H; Yang C; Huang W; Gui B; Shan B; Badal R; Yang Q; Xu Y
    BMC Infect Dis; 2018 Sep; 18(1):493. PubMed ID: 30268102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Tolerability of Doripenem in Hospitalized Children With Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infections and Pneumonia.
    Cannavino CR; Castaneda-Ruiz B; Redman R; Go O; Cirillo I; Barauskas V; Senatorova G; Emeryk A; Bradley JS
    Pediatr Infect Dis J; 2015 Nov; 34(11):1264-7. PubMed ID: 26226440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intra-abdominal and pelvic emergencies.
    Singh S; Khardori NM
    Med Clin North Am; 2012 Nov; 96(6):1171-91. PubMed ID: 23102483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital.
    Liu Q; Ren J; Wu X; Wang G; Wang Z; Wu J; Huang J; Lu T; Li J
    BMC Infect Dis; 2017 Sep; 17(1):637. PubMed ID: 28934938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete Genome Sequence of a Third- and Fourth-Generation Cephalosporin-Resistant Comamonas kerstersii Isolate.
    Moser AI; Campos-Madueno EI; Keller PM; Endimiani A
    Microbiol Resour Announc; 2021 Jul; 10(28):e0039121. PubMed ID: 34264111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empiric antibiotic selection strategies for healthcare-associated pneumonia, intra-abdominal infections, and catheter-associated bacteremia.
    Snydman DR
    J Hosp Med; 2012; 7 Suppl 1():S2-S12. PubMed ID: 23737334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imipenem/cilastatin in the treatment of serious bacterial infections.
    Chiodini PL; Geddes AM; Smith EG; Conlon CP; Farrell ID
    Rev Infect Dis; 1985; 7 Suppl 3():S490-5. PubMed ID: 3901212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010-2011.
    Hawser S; Hoban DJ; Badal RE; Bouchillon SK; Biedenbach D; Hackel M; Morrissey I
    J Chemother; 2015 Feb; 27(2):67-73. PubMed ID: 24548089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain.
    Ferrer R; Fariñas MC; Maseda E; Salavert M; Bou G; Díaz-Regañón J; López D; Lozano V; Gómez-Ulloa D; Fenoll R; Lara N; McCann E
    Rev Esp Quimioter; 2021 Dec; 34(6):639-650. PubMed ID: 34806858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.